It has been shown that the down regulation of AMPA receptors can lead to progression in neurodegenerative diseases such as Alzheimer disease, thus suggesting that inhibiting the PICK1-GluA2 interaction that is responsible for such down regulation may be an effective therapy for Alzheimer disease [52]. Here, GRIA2 is linked to Alzheimer disease.